Expression, purification, and in vivo administration of a promising anti-idiotypic HIV-1 vaccine

5Citations
Citations of this article
15Readers
Mendeley users who have this article in their library.
Get full text

Abstract

To date only a few neutralizing antibodies against HIV-1 exist. Since these neutralizing antibodies are only rarely found in sera of HIV-1 infected individuals an active vaccine is required. We recently developed murine anti-idiotypic antibody Ab2/3H6 against monoclonal antibody (mAb) 2F5, which is one of the most prominent neutralizing antibodies. Anti-idiotypic antibody Ab2/3H6 has been partially humanized and expressed as whole immunoglobulin G in Chinese hamster ovary cells in order to minimize the human anti-mouse antibody response. Here we describe the expression, purification, and immunohistochemical characterization of the chimeric Ab2/3H6 Fab fragment, which was finally used beside the whole IgG1 as an antigen for immunization of guinea pigs. The crude sera were screened for specific antibodies against the epitope of mAb 2F5 ELDKWA as well as for reactivity against HIV-1 gp41. © 2008 Humana Press.

Cite

CITATION STYLE

APA

Gach, J. S., Quendler, H., Ferko, B., Katinger, H., & Kunert, R. (2008). Expression, purification, and in vivo administration of a promising anti-idiotypic HIV-1 vaccine. Molecular Biotechnology, 39(2), 119–125. https://doi.org/10.1007/s12033-008-9054-7

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free